Unicycive (UNCY) Director Kenkare-Mitra Receives RSU Award

What Happened

• Sara Kenkare-Mitra, a director of Unicycive Therapeutics, was granted 47,941 restricted stock units (RSUs) on May 14, 2026. The reported acquisition price is $0 (this is a compensation award/derivative grant payable in common stock).

Key Details

• Transaction date: May 14, 2026; Amended Form 4 filed: July 28, 2026 (amendment indicates delayed reporting).
• Grant size: 47,941 RSUs; reported value in filing: $0.
• Vesting schedule (footnote): 19,976 RSUs vest immediately upon grant; the remaining 27,965 RSUs vest in monthly installments of 3,995 shares over 7 months beginning June 1, 2026, subject to continued service.
• RSUs payable solely in Unicycive common stock (per footnote).
• Shares owned after the transaction: not specified in the provided filing excerpt.

Context

• This is a compensation award (code A) of RSUs, not an open‑market purchase or sale. RSU grants are common for directors and provide stock if vesting conditions (here, continued service) are met; they do not necessarily signal immediate buying or selling intent. The filing was amended and reported over two months after the grant date, so the initial reporting was delayed.